Imagion presents ovarian cancer data at AACR conference
Filed with ASX · · 3 pages · English
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- 2022 R&D Tax Refund
- Appendix 4D
- Half-Year Results Release
- Non-renounceable Entitlement Offer Shortfall
- Imagion to complete the MagSense HER2 Phase 1 Study
Later from Imagion Biosystems
- Notice of Extraordinary General Meeting/Proxy Form
- Phase 1 Study Closure and Preliminary Performance
- Imagion Announces Positive Results from Phase 1 Study
- Imagion Announces CEO Departure
- Appendix 4E and Preliminary Final Report
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems